Altogether, these findings suggest that chidamide leveraged the immune‐mediated anti‐tumor effects of PD‐1 (+) cells, which could have potential synergistic effect with PD‐1 inhibitors or other immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.